Medtech stories we missed this week: Dec. 8, 2017

From Minimus Spine’s European distribution deal to Stimwave receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning.

1. Minimus Spine inks EU distribution deal

Minimus Spine announced in a Dec. 4 press releasethat it has signed its first European distribution deal with Italian company Moss and has completed its first commercial order. Moss has exclusive distribution rights to distribute in Italy, Germany, Switzerland and the U.K.

2. Elanix, Dermacon sign wound management development deal

Elanix Biotechnologies and Dermacon have signed an agreement to develop progenitor cell medical devices that help accelerate wound healing, according to a Dec. 1 press release. The new devices, called First Cover, will use Elanix’s progenitor cell technology and will be evaluated to accelerate healing in acute and chronic wounds. Dermacon will design progenitor cell matrix-based products for Elanix and guide the development and CE mark processes.

3. CSA Medical launches TruFreeze Rapid AV trial

CSA Medical announced in a Nov. 27 press release that it has enrolled its first patient into a multi-center prospective study that determines the effects of spray cryotherapy on patients who have esophageal cancer. The patient received treatment at the University of North Carolina’s Center for Esophageal Diseases and Swallowing.

Get the full story on our sister site, MassDevice.

From the Hospital Bed to the Finish Line Heidi Dohse was diagnosed with a rare arrhythmia in 1982 and has been 100% pacemaker dependent for over 30 years. With the help of wearable devices, she has been able to pursue her dream to become a competitive cyclist. You can hear her story and more when you register for DeviceTalks Boston, October 8-10. REGISTER NOW Use code FINISHLINE to save an additional 10%.